Triplet regimen yields 90 percent cure rate for XDR/MDR TB in latest study
An all-oral triplet regimen of bedaquiline, pretomanid, and linezolid leads to resolution of extensively drug-resistant (XDR) and multidrug-resistant (MDR) tuberculosis (TB) in 90 percent of patients, with no relapse for at least 6 months after treatment, the Nix-TB* study has shown.
